99 Wall Street, Suite 232, New York, NY 10005

Need Help? Call : (800) 991-3756

Class Action Cases

A class action has been filed on behalf of MGNX Investors. Click "Join this Class Action" above.

Attorneys

MacroGenics, Inc.

Join Class Action »

Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of MacroGenics, Inc. from February 6, 2019 through June 3, 2019 (the “Class Period”). The lawsuit seeks to recover damages for MacroGenics, Inc. investors under the federal securities laws.

If you bought MacroGenics, Inc. securities between February 6, 2019 through June 3, 2019, and would like to join the action, please click “Join This Class Action,” above.

Press Release

SHAREHOLDER ALERT: Zhang Investor Law Announces the Filing of a Securities Class Action Lawsuit Against MacroGenics, Inc.- MGNX 

New York, N.Y., September 19, 2019. Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of MacroGenics, Inc. (NASDAQ: MGNX) between February 6, 2019 and June 3, 2019, inclusive (the “Class Period”).
To join the MGNX class action, go to http://zhanginvestorlaw.com/cases/macrogenics-inc/ call Sophie Zhang, Esq. toll-free at 800-991-3756 or email info@zhanginvestorlaw.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT.

According to the lawsuit, throughout the Class Period concealed or misstated that: (1) the Company had conducted the progression-free survival (PFS) and first interim overall survival (OS) analyses for the SOPHIA trial by no later than October 10, 2018; (2) the October 2018 PFS analysis showed a 0.9 month improvement in PFS; and (3) the October 2018 OS interim analysis did not produce a statistically significant result and the interim OS Kaplan-Meier curves (a non-parametric statistic used to estimate the survival function from lifetime data) crossed in several spots (thereby violating the constant hazard assumption) and separated late. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 12, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://zhanginvestorlaw.com/cases/macrogenics-inc/ or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. of Zhang Investor Law toll free at 800-991-3756 or via e-mail at info@zhanginvestorlaw.com.

Zhang Investor Law represents investors worldwide.